Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of any of the following B-cell chronic LPD, as defined by WHO 2008 classification: small lymphocytic lymphoma/chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, Hodgkin's lymphoma.~2. Occurrence of ITP diagnosed on the basis of predefined criteria.~3. Not likely to necessitate any cytotoxic treatment for the following 6 months, according to clinical stage and performance status.~4. Platelet count less than 30,000/µL; patients with platelet count between 30 and 50,000/µL only in case of bleeding signs or symptoms.~5. Age greater than or equal to 18 years.~6. Absence of a personal or family (up to first degree relatives) history of venous or arterial thromboembolism.~7. ECOG performance status ≤2.~8. Adequate liver and renal function.~9. Absence of active Hepatitis B (HBsAg+ or HBV-DNA+), Hepatitis C (HCV-Ab+), or HIV infection.~9) Provided informed consent. 10) Negative pregnancy test or lactation 11) No antiplatelet or anticoagulant ongoing treatments~Exclusion Criteria:~1. Subjects with any clinically relevant abnormality, other than LPD or ITP, or any other medical condition or circumstance, which in the opinion of the investigator makes the subject unsuitable for participation in the study.~2. Subjects with any concurrent malignant disease other that the LPD and/or a recent history of cancer treatment with systemic chemotherapy and/or radiotherapy. Exception: Subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~3. Subjects with screening bone marrow fibers of either MF Grade 3 using European Consensus scale or Grade 4 using Bauermeister scale (see Appendix 1).~4. Subjects with a QTc \>450 msec or \> 480 msec for subjects with Bundle Branch Block.~5. Subjects with recent history of alcohol/drug abuse as determined by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eltrombopag Olamine (Type: OTHER): Eltrombopag Olamine Initial dose 50 mg/day for 14 days. Then adjusted according to platelet count

Based on this trial design, predict the completion outcome and termination type (if applicable).